SeqWright Continues Expansion of Next-Generation Sequencing Capabilities
News Jan 19, 2011
SeqWright Inc., continues to make significant strides to position itself as the Next-Generation Sequencing Provider of choice for 2011. SeqWright's ongoing success can be attributed to the company's ability to respond quickly to customer's demands and by investing in key genomics technologies. Building on this success, SeqWright announced the expansion of its Next-Generation Sequencing capacity by the acquisition of a second Illumina HiSeq 2000.
SeqWright has also expanded its bioinformatics capabilities with the acquisition of the PowerWulf GRaNDE Compute Engine from PSSC Labs, significantly increasing workflow. SeqWright's bioinformatics experts can map Next-Generation sequencing runs in under 24 hours, map multiple jobs at once, and map from multiple platforms simultaneously. This allows SeqWright to process more large-scale Next-Generation sequencing projects in less time, improving operational efficiency and increasing throughput.
SeqWright's Next-Generation data management system, Isilon IQ, has also been augmented with increased storage and archiving tape capacity and a dedicated archiving server. These changes enhance SeqWright's regulatory compliance by meeting the back-up requirements of customers and regulatory agencies, consistent with SeqWright's focus on expanding its GLP and CLIA offerings.
With the Roche 454 GS FLX Titanium, AB SOLiD 4 and Illumina HiSeq 2000 Next-Generation Sequencing Platforms, an array of sequence capture and target enrichment technologies, and advanced data analysis and storage, SeqWright is positioned to offer the best solutions under one roof.
SeqWright's Next-Generation services continue to expand and includes de Novo sequencing, SNP analysis (regulatory validated for the Roche 454 GS FLX Titanium), RNA and cancer genome sequencing. SeqWright continues to focus on offering project-specific solutions to its wide range of clients, from pharmaceutical companies to academia, while continuing to evaluate the market for the next advancement in the life science industry.